Paratek Pharmaceuticals IncChange company Symbol lookupSelect an option...PRTK Paratek Pharmaceuticals IncDARE Dare Bioscience IncREXR-C Rexford Industrial Realty IncAQNA Algonquin Power & Utilities CorpNAOV Nanovibronix IncIOT Samsara IncGSIT GSI Technology IncGME GameStop CorpCMBM Cambium Networks CorpS SentinelOne IncGo
Change company Symbol lookup
Select an option...
PRTK Paratek Pharmaceuticals Inc
DARE Dare Bioscience Inc
REXR-C Rexford Industrial Realty Inc
AQNA Algonquin Power & Utilities Corp
NAOV Nanovibronix Inc
IOT Samsara Inc
GSIT GSI Technology Inc
GME GameStop Corp
CMBM Cambium Networks Corp
S SentinelOne Inc
Health Care : Pharmaceuticals | Small Cap Growth
Company profileParatek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Beat Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 9, 2023 | -$0.35 | Q1 Consensus of 2 analysts | -$0.42 | Difference from consensus | 16.67% | Q2 Earnings will announce | (Unconfirmed) August 1, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
PRTK's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.